ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
“Challenges which others have deemed unsolvable are the problems we are solving.”
~ Jeffrey S. Aronin
Paragon founder, chairman and CEO
Portfolio
Since 2017, Paragon has successfully launched seven portfolio companies, including a recent upsized IPO, while maintaining a consistent flow of companies in development.
Leveraging its proprietary fibroblast technology platform to expand an innovative gene therapy pipeline, developing personalized treatments for underserved disorders, including epidermolysis bullosa and localized scleroderma.
Concentrating on cell therapy treatments for serious diseases with high, unmet needs with an initial focus on the eye, including geographic atrophy age-related macular degeneration and advanced retinitis pigmentosa.
Creating treatments for central nervous system movement disorders and fluency disorders, including Tourette syndrome and childhood-onset fluency disorder (stuttering) in adults.
Evozyne is combining the exquisite complexity of nature with advanced machine learning to create novel proteins with extraordinary impact across a variety of industries.
Commercializing biopharmaceutical treatment options for people living with rare diseases, including disorders of sleep and wakefulness, such as narcolepsy, Prader-Willi syndrome and myotonic dystrophy.
Assisting radiologists to significantly improve clinical assessment and characterization of cancerous breast abnormalities through artificial intelligence-driven technology that enhances clinical insights.
News
First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that the first adult patient [...]
Jon DeVries Named Qlarity Imaging Chief Executive Officer
Chicago, September 9, 2020 – Life science innovator Paragon Biosciences announced the appointment of Jon T. DeVries as the new chief executive officer of its portfolio company, Qlarity Imaging, a leading artificial intelligence [...]
Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone
– Half of participants are now enrolled in study evaluating ecopipam (EBS-101) as a potential first-in-class treatment for pediatric patients with Tourette Syndrome – Chicago – September 1, 2020 – Emalex Biosciences, [...]
First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and [...]
Jon DeVries Named Qlarity Imaging Chief Executive Officer
Chicago, September 9, 2020 – Life science innovator Paragon Biosciences announced the appointment of Jon T. DeVries as the new chief executive officer of its [...]
Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone
– Half of participants are now enrolled in study evaluating ecopipam (EBS-101) as a potential first-in-class treatment for pediatric patients with Tourette Syndrome – [...]
First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and [...]
Jon DeVries Named Qlarity Imaging Chief Executive Officer
Chicago, September 9, 2020 – Life science innovator Paragon Biosciences announced the appointment of Jon T. DeVries as the new chief executive officer of its [...]
Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone
– Half of participants are now enrolled in study evaluating ecopipam (EBS-101) as a potential first-in-class treatment for pediatric patients with Tourette Syndrome – [...]
